Skip to main content
. Author manuscript; available in PMC: 2015 Dec 1.
Published in final edited form as: J Leuk (Los Angel). 2014 Sep 24;2(5):158. doi: 10.4172/2329-6917.1000158

Figure 4. Determining the correlation between amount of BCLxl and oncogenic potency.

Figure 4

a) Western blot of HEK293T cells transfected with the indicated ratios of MIT-GFP and MIT-BCLxl. b) Kaplan-Meier survival curve of mice receiving Tet-O-MYC bone marrow infected with equal amounts of the indicated retroviral supernatant containing decreasing amounts of MIT-BCLxl virus. Five mice received bone marrow infected with each viral supernatant. c) Western blot of splenocytes from leukemic mice were performed as indicated above.